{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-017870","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.401736+00:00","generated_at":"2026-05-22T03:55:13.650375+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"PDS Biotech reports preclinical flu vaccine data with Infectimune at IMMUNOLOGY2025","bullets":["Infectimune-based flu vaccine elicited multifunctional, influenza-specific CD4 T cells with cytotoxic characteristics in preclinical studies.","Preclinical ferret studies showed neutralization of H3N2 influenza strains from 2014 to 2021 using COBRA antigens.","Studies were funded by NIAID's CIVR-HRP and presented by Dr. Sant (U of Rochester) and Dr. Allen (Cleveland Clinic).","Company reaffirms focus on VERSATILE-003 Phase 3 trial for Versamune HPV in HPV16-positive HNSCC."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-017870","json":"https://secwatch.observer/filing/0001140361-25-017870.json","markdown":"https://secwatch.observer/filing/0001140361-25-017870.md","text":"https://secwatch.observer/filing/0001140361-25-017870.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125017870/0001140361-25-017870-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036125017870/ef20048584_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:55:13.650375+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}